Hyaluronic Acid Eases Joint Damage of Hemophilia, Study Reports
Adults with hemophilia and ankle joint damage taking part in a yearlong pilot study largely reported that two…
Articles by Steve Bryson, PhD
Cancer Therapies May Boost Risk of Acquired Hem A, Analysis Says
Immune checkpoint inhibitors (ICIs) used for cancer treatment may be associated with an increased likelihood of developing acquired hemophilia…
Hepatitis C Raises Liver Cancer Risk in Men With Hemophilia, Study Says
Hepatitis C virus (HCV) infection remains a major risk factor for hepatocellular carcinoma — the most common type of liver…
Switching to Elocta Helps Reduce Hem A Joint Bleeds in France
People in France with severe hemophilia A who switched to Elocta (efmoroctocog alfa) — an extended half-life replacement…
Elocta Found to Reduce Elbow, Knee Bleeds in Severe Hem A Patients
One year of treatment with Elocta (efmoroctocog alfa) — an extended half-life replacement therapy known as Eloctate in the…
BBM-H901, Gene Therapy for Hem B, Shows Efficacy at 1 Year in Pilot Trial
The gene therapy BBM-H901 increased factor IX activity in 10 men with moderate to severe hemophilia B, while reducing bleeds…
1st Gene Therapy for Hem B Granted Priority Review by the FDA
The U.S. Food and Drug Administration (FDA) has accepted — under priority review — a marketing application for EtranaDez…
Arthritis Medicine Helps Prevent FVIII Inhibitors in Animal Study
Treatment with abatacept, a medication approved for rheumatoid arthritis, prevented the formation of inhibitors against hemophilia A replacement therapies…
FDA Lifts Hold on Phase 3 Trial of Gene Therapy SB-525 for Hem A
The U.S. Food and Drug Administration (FDA) has lifted a clinical hold on the Phase 3 trial testing the safety…
Eptacog Beta Effectively Treats Bleeds in Children With Hem A or B
Eptacog beta was safe and almost 100% effective at stopping bleeds within 24 hours in boys ages 12 and younger…